Efavirenz/lamivudine/tenofovir

Last updated
Efavirenz/lamivudine/tenofovir
Combination of
Efavirenz Non-nucleoside reverse transcriptase inhibitor
Lamivudine Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil Nucleoside reverse transcriptase inhibitor
Clinical data
Trade names Symfi, Symfi Lo
Other namesEFV/3TC/TDF
AHFS/Drugs.com Professional Drug Facts
MedlinePlus a618028
License data
Pregnancy
category
  • Contraindicated
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Symfi among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. [1] [2] [3] It combines efavirenz, lamivudine, and tenofovir disoproxil. [3] As of 2019, it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir. [4] It is taken by mouth. [1] [2] [3]

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness. [3] Severe side effects may include depression, psychosis, or osteonecrosis. [3] In those with a history of epilepsy, it may increase the frequency of seizures. [3] Greater care should also be taken in those with kidney problems. [3] Its use during pregnancy appears to be unsafe. [1] [2]

It is on the World Health Organization's List of Essential Medicines. [5] The combination received tentative approval in the United States in 2014, [6] and was granted approval in February 2018. [7] [8] Its availability and importance is supported by Medecins Sans Frontieres. [3] It is available as a generic medication. [9] [10] [11]

References

  1. 1 2 3 4 "Symfi- efavirenz, lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 25 September 2021.
  2. 1 2 3 4 "Symfi Lo- efavirenz, lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 25 September 2021.
  3. 1 2 3 4 5 6 7 8 "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO). Archived from the original on October 26, 2015.
  4. ↑ World Health Organization (July 2019). Policy brief: update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. hdl: 10665/325892 . WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
  5. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. ↑ "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". U.S. Food and Drug Administration (FDA). Archived from the original on February 27, 2016. Retrieved 13 December 2017.
  7. ↑ "Drug Approval Package: Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 9 October 2018. Archived from the original on April 15, 2021. Retrieved 15 August 2020.
  8. ↑ "Drug Approval Package: Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 24 November 2018. Retrieved 15 August 2020.[ dead link ]
  9. ↑ "Office of Generic Drugs 2020 Annual Report". U.S. Food and Drug Administration (FDA). Retrieved 12 February 2021.[ dead link ]
  10. ↑ "Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on October 19, 2020. Retrieved 25 September 2021.
  11. ↑ "Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on October 19, 2020. Retrieved 25 September 2021.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.